Cargando…
CD44/Folate Dual Targeting Receptor Reductive Response PLGA-Based Micelles for Cancer Therapy
In this study, a novel poly (lactic-co-glycolic acid) (PLGA)-based micelle was synthesized, which could improve the therapeutic effect of the antitumor drug doxorubicin hydrochloride (DOX) and reduce its toxic and side effects. The efficient delivery of DOX was achieved by active targeting mediated...
Autores principales: | Zhang, Ru, Jiang, Yunying, Hao, Linkun, Yang, Yang, Gao, Ying, Zhang, Ningning, Zhang, Xuecheng, Song, Yimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960309/ https://www.ncbi.nlm.nih.gov/pubmed/35359873 http://dx.doi.org/10.3389/fphar.2022.829590 |
Ejemplares similares
-
Preparation and in vivo/in vitro characterization of Ticagrelor PLGA sustained-release microspheres for injection
por: Hao, Linkun, et al.
Publicado: (2021) -
Tetracycline-grafted mPEG-PLGA micelles for bone-targeting and osteoporotic improvement
por: Que, Yunduan, et al.
Publicado: (2022) -
Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery
por: Yang, Yishun, et al.
Publicado: (2018) -
HA-Coated PLGA Nanoparticles Loaded with Apigenin for Colon Cancer with High Expression of CD44
por: Yang, Bo, et al.
Publicado: (2023) -
Fabrication of pH/Redox Dual-Responsive Mixed Polyprodrug Micelles for Improving Cancer Chemotherapy
por: Luo, Ji, et al.
Publicado: (2022)